The proposed Greater Bay Area Community Clinical Oncology Program will seek to stimulate the delivery of optimal cancer treatment to community cancer patients in th North and East San Francisco Bay Area Counties. By consolidating and expanding three experienced Cooperative Group Oncology Program members, the CCOP will become a new regional network capable of helping NCI and cooperative clinical trial groups identify and test new treatments and cancer control hypotheses. With experience in accessing, minority populations,.the proposed CCOP will involve underserved and economicallv disadvantaged populations in both treatment and cancer control research studies which should not only improve cure rates, but will significantly add to the body of social science knowledge that should help reduce barriers to early detection and prompt effective treatment. The pediatric component of the CCOP will accrue 90% of all eligible cancer patients within its current referral base, and will expand its referral area through closer communication with all physicians participating in the CCOP. Since the CCOP will be built on the organizational and administrative foundations of former CCOP members, it will have the expertise to begin accruing patients immediately upon approval. Proven mechanisms and experienced personnel are in place to deal with protocol selection, submission to and review by hospital investigational review boards, randomization of patients and collection of data. The principal CCOP research base will be the Eastern Cooperative Oncology Group. Affiliation agreements have also been signed with the Children's Cancer Study Group, the National Surgical Adjuvant Project for Breast and Bowel Cancers, and the Northern California Cancer Program. In the first year of the program, participating physicians plan to accrue 164 patients to clinical research protocols, and an additional 30 patients to cancer control research protocols. Physicians in the CCOP plan to be actively involved in the activities of the research bases, and anticipate participation at group meetings, committee meetings, and in the development of future protocols. The CCOP will also plan and conduct educational programs to keep community physicians abreast of the latest therapeutic and cancer control research protocols from which their patients might benefit.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
1U10CA045461-01
Application #
3558647
Study Section
(SRC)
Project Start
1989-06-01
Project End
1992-05-31
Budget Start
1989-06-01
Budget End
1990-05-31
Support Year
1
Fiscal Year
1989
Total Cost
Indirect Cost
Name
Bay Area Tumor Institute
Department
Type
DUNS #
040003402
City
Oakland
State
CA
Country
United States
Zip Code
94609
Ji, Yongli; Rankin, Cathryn; Grunberg, Steven et al. (2015) Double-Blind Phase III Randomized Trial of the Antiprogestin Agent Mifepristone in the Treatment of Unresectable Meningioma: SWOG S9005. J Clin Oncol 33:4093-8
Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64
Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7
Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5
Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48
Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Kim, Edward S; Moon, James; Herbst, Roy S et al. (2013) Phase II trial of carboplatin, paclitaxel, cetuximab, and bevacizumab followed by cetuximab and bevacizumab in advanced nonsquamous non-small-cell lung cancer: SWOG S0536. J Thorac Oncol 8:1519-28
Smalley, Stephen R; Benedetti, Jacqueline K; Haller, Daniel G et al. (2012) Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 30:2327-33
Schott, Anne F; Barlow, William E; Albain, Kathy S et al. (2012) Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. Oncologist 17:179-87

Showing the most recent 10 out of 54 publications